TAR-200 Appears Highly Efficacious, Safe in BCG-Unresponsive NMIBC
Results from the SunRISe-1 trial showed that TAR-200 monotherapy achieved a complete response rate of 82.4% in patients with BCG-unresponsive NMIBC.
Previous Post
Draft of major MAHA report calls for more education, less regulation — and offers few policies
Next Post
Balancing Breast Cancer Breakthroughs With Clinical, Financial, and Diagnostic Barriers: Michael Hassett, MD, MPH
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago